The KDM5B Knockout LoVo Polyclonal Cells represent a CRISPR/Cas9-mediated gene disruption model of the KDM5B demethylase, produced as a polyclonal knockout cell population. This product leverages the LoVo colorectal adenocarcinoma host cell line, offering a genetically ablated KDM5B background for investigating chromatin-dependent transcriptional regulation. Unlike monoclonal isolates, the polyclonal format preserves biological heterogeneity, enabling robust population-level analyses of KDM5B loss-of-function phenotypes.
The host LoVo cell line originates from a human metastatic colon adenocarcinoma with a Dukes’ type C, grade IV classification, serving as an established in vitro model for aggressive colorectal cancer biology. These adherent epithelial cells harbor mutations in APC, KRAS, and TP53, recapitulating key genetic drivers of advanced disease. The LoVo background provides a clinically relevant context for examining epigenetic contributions to metastatic progression, chemoresistance, and cancer stem cell maintenance.
KDM5B functions as an H3K4me2/3 histone demethylase that transcriptionally represses target loci by removing activating methyl marks from histone H3. In colorectal cancer, KDM5B is regulated upstream by E2F transcription factors, MYC, NOTCH1, and the PI3K/AKT pathway, and it interacts with transcriptional corepressor complexes containing RB1, HDAC1/2, SIN3A, and components of Polycomb repressive complex 2 (EZH2, SUZ12). Its catalytic activity silences tumor suppressors such as CDKN1A (p21), CDKN1B (p27), and p16INK4a, while simultaneously maintaining expression of stemness factors including OCT4 and SOX2, thereby coordinating a balance between proliferation and self-renewal.
In the LoVo cellular context, KDM5B disruption provides a powerful tool for dissecting the epigenetic mechanisms driving colorectal cancer stemness and metastasis. Abrogation of KDM5B demethylase activity leads to increased promoter H3K4me3 levels and re-expression of silenced tumor suppressors, potentially reversing the stem cell-like phenotype. This polyclonal knockout model enables interrogation of KDM5B-dependent chromatin remodeling, derepression of lineage commitment programs, and attenuation of tumor-initiating capacity, with direct implications for understanding how chromatin modifiers contribute to disease progression.
Key research applications include chromatin immunoprecipitation (ChIP-qPCR) for quantitative profiling of H3K4me3 at target gene promoters, RNA-seq-based transcriptome profiling to identify KDM5B-regulated networks, and quantitative western blotting or RT-qPCR to assess changes in p21 and HOX gene expression. Functional assays such as sphere formation, colony formation, and migration/invasion quantify stemness and metastatic potential, while drug sensitivity screens evaluate response to demethylase inhibitors. These polyclonal knockout cells are suited for epigenetic drug target validation, mechanistic studies of Notch and RB/E2F pathway crosstalk, and functional dissection of cancer cell plasticity. For additional technical information, please contact Ascent Research.
